[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Intrinsic Therapeutics, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":138},{"warningLetters":4,"total":137},[5,33,55,76,97,118],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":28,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},2317,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-11-22T14:20:00Z\">11\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-09T05:00:00Z\">11\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finvitrx-therapeutics-inc-630712-11092022\">Invitrx Therapeutics, Inc.\u003C\u002Fa>"," Division of Biological Products Operations II","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Habib Torfi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Invitrx Therapeutics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>20503 Crescent Bay Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lake Forest\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92630\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Biological Products Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 9, 2022\u003C\u002Fp>\n\n\u003Cp>[OBPO 22-630712]\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Torfi:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Invitrx Therapeutics, Inc. (“Invitrx”), located at 20503 Crescent Bay Drive, Lake Forest, CA 92630, conducted between March 1, 2022 and March 22, 2022, the United States Food and Drug Administration (FDA) documented that you manufacture cellular and acellular products for allogeneic use. This includes the following products (collectively “your products”): a human umbilical cord derived cellular product, Invitra UC-MSC™, and exosome products, Invitra EX™ and Invitra EV-OP™. You have distributed your products directly to healthcare professionals and medical facilities throughout the United States.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Your products are intended to be administered by injection, ophthalmically, or by nebulization and purport to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered during the inspection and information available on your website, www.invitrx.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your umbilical cord derived cellular product, Invitra UC-MSC™, is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Invitrx does not qualify for any exception in 21 CFR 1271.15, and your umbilical cord derived cellular product, Invitra UC-MSC™, fails to meet all the criteria in 21 CFR 1271.10(a). Specifically, your umbilical cord derived cellular product, Invitra UC-MSC™, fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” This product is not intended to perform the same basic function or functions of the umbilical cord in the recipient as in the donor, such as serving as a conduit. Rather, using this product to treat orthopedic conditions, such as osteoarthritis, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>In addition, Invitra UC-MSC™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement.\u003C\u002Fp>\n\n\u003Cp>Therefore, Invitra UC-MSC™ is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because this HCT\u002FP does not meet all the criteria in 21 CFR 1271.10(a), and Invitrx does not qualify for any exception in 21 CFR 1271.15, the product is regulated as a drug as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>With regard to your unapproved exosome products, Invitra EXTM and Invitra EV-OPTM, we direct your attention to FDA’s Public Safety Notification on Exosome Products, available at \u003Ca>www.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublicsafety-notification-exosome-products\u003C\u002Fa>. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fp>\n\n\u003Cp>Your exosome products, marketed for the treatment of diseases and conditions in humans, are regulated as drugs under the FD&amp;C Act and biological products under the PHS Act and are subject to premarket review and approval requirements.\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act, 21 CFR Parts 210 and 211, and 21 CFR Part 1271. Many of the deviations are repeat deficiencies that FDA documented during the March-April 2019 inspection of your firm. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant deviations applicable to your products. FDA also identified additional significant deviations upon further review of the information collected during the March 2022 inspection, as discussed below. These deviations, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of product manufactured since March 2020, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure of a responsible person to determine and document the eligibility of a cell or tissue donor based upon the results of donor screening and donor testing [21 CFR 1271.50(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Invitrx is the establishment responsible for making the donor eligibility determination, but since operations began, Invitrx has failed to determine and document the eligibility of hundreds of tissue donors. Tissue from these donors was used to manufacture your products, including Invitra UC-MSCTM.\u003C\u002Fp>\n\n\u003Cp>b. Invitrx has not reviewed relevant medical records it has received from its umbilical cord tissue suppliers to determine donor eligibility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm has failed to validate the aseptic processes used to manufacture Invitra UC-MSCTM, Invitra EXTM, and Invitra EV-OPTM. By the nature of their routes of administration, these products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. During the inspection, FDA investigators observed primary product containers for products purporting to be sterile, including vial caps for Invitra EV-OP™, being stored on a shelf in an open bag in your aseptic processing area, specifically, cleanroom \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The caps are received in bulk and do not undergo further cleaning or sterilization.\u003C\u002Fp>\n\n\u003Cp>c. Your environmental monitoring procedures for your firm’s aseptic processing area where your products are manufactured are inadequate.\u003Cbr>\nFor example:\u003C\u002Fp>\n\n\u003Cp>i. You have not performed environmental monitoring of the aseptic processing area on a sufficient frequency to demonstrate control of this area during manufacturing.\u003C\u002Fp>\n\n\u003Cp>ii. You have not established environmental monitoring using settle plates.\u003C\u002Fp>\n\n\u003Cp>iii. Your written procedure in place at the time of the inspection, SOP Q-QA-010, Environmental Monitoring Program (Effective Date 01\u002F02\u002F2019), states that sampling is to be performed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This procedure is insufficient to demonstrate control of the aseptic processing area during manufacturing because it does not include air sampling for non-viable and viable particulates during aseptic processing operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to satisfy general biological products standards for sterility testing [21 CFR 610.12].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm began conducting in-house sterility testing in January 2021. Your firm was still conducting in-house sterility testing at the time of the inspection, but your sterility testing method(s) has not been validated to demonstrate that it can reliably and consistently detect the presence of viable contaminating microorganisms in your products. This also represents a failure to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods you employ, as required by 21 CFR 211.165(e).\u003C\u002Fp>\n\n\u003Cp>b. The number of samples for sterility testing specified in your “Batch Record for \u003Cstrong>(b)(4)\u003C\u002Fstrong> WJ MSC-Derived Exosomes,” used to manufacture Invitra EX™, is not appropriate in that it does not consider the size and volume of the final product lot.\u003Cbr>\n\u003Cbr>\nc. Your firm did not document performance or results of sterility testing of your products that was conducted in-house from January 2021 to March 2022.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example, the manufacturing processes for your products have not been validated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. \u003C\u002Fstrong>For example, you have not established appropriate specifications and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)].\u003C\u002Fstrong> For example, you failed to appropriately test or examine before release for use \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) used in your products and the vials that contain the final product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine the appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> For example, you have assigned two-year expiration dates to your exosome products without supporting data.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)]\u003C\u002Fstrong>. For example, you have not investigated complaints received related to your products, including complaints involving reports of adverse events, in accordance with your written procedures, SOP Q-QC-005, Adverse Events Evaluating and Reporting, Rev. 00, Ver. 00 (Effective Date 01\u002F27\u002F2021) and SOP Q-QA-006, Complaint Investigation, Rev. 1.0 (Effective Date 09\u002F25\u002F2019).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not maintained batch production records for your in-process conditioned media or for your finished products, including Invitra UC-MSC and Invitra EV-OP, which are manufactured from human umbilical cord tissue.\u003C\u002Fp>\n\n\u003Cp>b. You have not documented the identity of each batch of component or in-process material used, for example the in-process conditioned media used to manufacture your products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use [21 CFR 211.63].\u003C\u002Fstrong> For example, incubators used for sterility testing have not been qualified for that use.\u003C\u002Fp>\n\n\u003Cp>We also note that some of the written procedures collected during the inspection that your firm uses to manufacture Invitra UC-MSC™, Invitra EX™, and Invitra EV-OP™ were identified as “draft.” Your response to this letter should include copies of any revised procedures along with documentation of their implementation.\u003C\u002Fp>\n\n\u003Cp>During the inspection, FDA investigators documented that you continued to manufacture and distribute products regulated as drugs and biological products without an approved BLA or an IND in effect for those products (Invitra CBSC Suspension™, Invitra WJ-C™, Invitra WJ-Acellular, Invitra A™, and Invitra AF™) until December 2020, after FDA issued a Warning Letter to your firm in March 2020, notifying you that because those products were not the subject of an approved BLA and because there was not an IND in effect for them, your actions violated the FD&amp;C Act and the PHS Act. The March 2020 Warning Letter also detailed your CGMP violations in the manufacture of those products.\u003C\u002Fp>\n\n\u003Cp>FDA’s March 2020 Warning Letter also notified you that, as a general matter, exosome products intended to treat diseases or conditions in humans are regulated as drugs and biological products and are subject to premarket review and approval requirements. After FDA brought this to your attention, you continued to manufacture and distribute exosome products, including Invitra EX™, and you started manufacturing another exosome product, Invitra EV-OP.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your correspondence, dated April 25, 2022, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response and determined that the response is inadequate. You state that you have, “suspended all manufacture of all clinical drug substance and drug product batches at the 20503 Crescent Bay Drive, Lake Forest California facility intended for use in domestic clinical trials.” It is unclear from this statement whether you have suspended manufacture of all products identified in the FDA-483. Further, it is unclear, based on your response, whether you will manufacture your products at any of your other locations for distribution. Your response also describes “interim control[s]” you plan to implement prior to completing certain corrective actions, which suggests that Invitrx will resume manufacturing prior to adequately addressing the existing deficiencies.\u003C\u002Fp>\n\n\u003Cp>Additionally, we cannot fully assess the adequacy of your responses to many of the observations because they do not provide sufficient detail on the corrective actions you state that you have implemented, lack a timeline for completion of all necessary corrective actions, and fail to provide supporting documentation for your planned corrective actions.\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address the failure to have an IND in effect for clinical investigations of your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>We acknowledge that, in your response, you commit to recall distributed product within expiry after performing a risk assessment. Your response to this letter should include the outcome of this assessment and any subsequent actions.\u003C\u002Fp>\n\n\u003Cp>Finally, during the inspection, your firm described certain products that it manufactures to the FDA investigators as intended for autologous use. However, based on the information obtained during the inspection and included in your correspondence regarding the FDA-483, including information on the customers to whom you are distributing, it is unclear whether these products are also intended for allogeneic use in a first-degree or second-degree blood relative. Please clarify the intended use of these products.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions may include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed and explain your rationale for your continued manufacture and distribution of products that were the subject of FDA’s March 2020 Warning Letter. We also request that you clarify whether you will continue manufacturing at any of your other locations under the “interim control[s]” described in your response prior to completing all planned corrective actions.\u003C\u002Fp>\n\n\u003Cp>If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion.\u003C\u002Fp>\n\n\u003Cp>We also request your attendance at a Regulatory Meeting to discuss the status of the specific steps you have taken since the inspection to address any violations. We will host the meeting at the FDA Lost Angeles District Office located at 19701 Fairchild, Irvine, CA 92612 on either Tuesday, \u003Cstrong>December 13, 2022, from 9:00am to 10:00am&nbsp;\u003C\u002Fstrong>Pacific Time or Wednesday, \u003Cstrong>December 14, 2022, from 10:00am to 11:00am Pacific&nbsp;\u003C\u002Fstrong>\u003Cstrong>Time\u003C\u002Fstrong>. This meeting will allow you to ask questions and provide FDA with additional information regarding the implementation of your corrective actions. Please contact Amy Graf, Compliance Officer, using the information below, date preference by Tuesday,&nbsp;\u003Cstrong>November 15, 2022\u003C\u002Fstrong>. Please provide a list of attendees with title and company name, if other than Invitrx, as well as a list of any questions to ensure the appropriate FDA parties are in attendance, by Wednesday, \u003Cstrong>November 30, 2022\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Your response should be emailed to Amy.Graf@fda.hhs.gov or sent to the following address: Amy Graf, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003Cbr>\n\u003Cbr>\ncc:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Invitrx manufactures human umbilical cord derived cellular products for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, branded as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, branded as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, using the same manufacturing process used for Invitra UC-MSC\u003Csup>TM\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>Invitrx manufactures exosome products for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, branded as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, branded as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, using the same manufacturing process used for Invitra EX\u003Csup>TM\u003C\u002Fsup>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nHabib Torfi\n\nRecipient Title\n\nChief Executive Officer\n\nInvitrx Therapeutics, Inc.\n\n20503 Crescent Bay Drive\n\nLake Forest, CA 92630\n\nUnited States\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nWARNING LETTER\n\nNovember 9, 2022\n\n[OBPO 22-630712]\n\nDear Mr. Torfi:\n\nDuring an inspection of your firm, Invitrx Therapeutics, Inc. (“Invitrx”), located at 20503 Crescent Bay Drive, Lake Forest, CA 92630, conducted between March 1, 2022 and March 22, 2022, the United States Food and Drug Administration (FDA) documented that you manufacture cellular and acellular products for allogeneic use. This includes the following products (collectively “your products”): a human umbilical cord derived cellular product, Invitra UC-MSC™, and exosome products, Invitra EX™ and Invitra EV-OP™. You have distributed your products directly to healthcare professionals and medical facilities throughout the United States.1 Your products are intended to be administered by injection, ophthalmically, or by nebulization and purport to be sterile.\n\nInformation and records gathered during the inspection and information available on your website, www.invitrx.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour umbilical cord derived cellular product, Invitra UC-MSC™, is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nInvitrx does not qualify for any exception in 21 CFR 1271.15, and your umbilical cord derived cellular product, Invitra UC-MSC™, fails to meet all the criteria in 21 CFR 1271.10(a). Specifically, your umbilical cord derived cellular product, Invitra UC-MSC™, fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” This product is not intended to perform the same basic function or functions of the umbilical cord in the recipient as in the donor, such as serving as a conduit. Rather, using this product to treat orthopedic conditions, such as osteoarthritis, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nIn addition, Invitra UC-MSC™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement.\n\nTherefore, Invitra UC-MSC™ is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because this HCT\u002FP does not meet all the criteria in 21 CFR 1271.10(a), and Invitrx does not qualify for any exception in 21 CFR 1271.15, the product is regulated as a drug as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\n\nWith regard to your unapproved exosome products, Invitra EXTM and Invitra EV-OPTM, we direct your attention to FDA’s Public Safety Notification on Exosome Products, available at www.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublicsafety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\n\nYour exosome products, marketed for the treatment of diseases and conditions in humans, are regulated as drugs under the FD&C Act and biological products under the PHS Act and are subject to premarket review and approval requirements.\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act, 21 CFR Parts 210 and 211, and 21 CFR Part 1271. Many of the deviations are repeat deficiencies that FDA documented during the March-April 2019 inspection of your firm. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\n\nAt the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant deviations applicable to your products. FDA also identified additional significant deviations upon further review of the information collected during the March 2022 inspection, as discussed below. These deviations, involving over (b)(4) vials of product manufactured since March 2020, include, but are not limited to, the following:\n\n1. Failure of a responsible person to determine and document the eligibility of a cell or tissue donor based upon the results of donor screening and donor testing [21 CFR 1271.50(a)]. For example:\n\na. Invitrx is the establishment responsible for making the donor eligibility determination, but since operations began, Invitrx has failed to determine and document the eligibility of hundreds of tissue donors. Tissue from these donors was used to manufacture your products, including Invitra UC-MSCTM.\n\nb. Invitrx has not reviewed relevant medical records it has received from its umbilical cord tissue suppliers to determine donor eligibility.\n\n2. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. Your firm has failed to validate the aseptic processes used to manufacture Invitra UC-MSCTM, Invitra EXTM, and Invitra EV-OPTM. By the nature of their routes of administration, these products purport to be sterile and are expected to be sterile.\n\nb. During the inspection, FDA investigators observed primary product containers for products purporting to be sterile, including vial caps for Invitra EV-OP™, being stored on a shelf in an open bag in your aseptic processing area, specifically, cleanroom (b)(4). The caps are received in bulk and do not undergo further cleaning or sterilization.\n\nc. Your environmental monitoring procedures for your firm’s aseptic processing area where your products are manufactured are inadequate.\n\nFor example:\n\ni. You have not performed environmental monitoring of the aseptic processing area on a sufficient frequency to demonstrate control of this area during manufacturing.\n\nii. You have not established environmental monitoring using settle plates.\n\niii. Your written procedure in place at the time of the inspection, SOP Q-QA-010, Environmental Monitoring Program (Effective Date 01\u002F02\u002F2019), states that sampling is to be performed (b)(4). This procedure is insufficient to demonstrate control of the aseptic processing area during manufacturing because it does not include air sampling for non-viable and viable particulates during aseptic processing operations.\n\n3. Failure to satisfy general biological products standards for sterility testing [21 CFR 610.12]. For example:\n\na. Your firm began conducting in-house sterility testing in January 2021. Your firm was still conducting in-house sterility testing at the time of the inspection, but your sterility testing method(s) has not been validated to demonstrate that it can reliably and consistently detect the presence of viable contaminating microorganisms in your products. This also represents a failure to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods you employ, as required by 21 CFR 211.165(e).\n\nb. The number of samples for sterility testing specified in your “Batch Record for (b)(4) WJ MSC-Derived Exosomes,” used to manufacture Invitra EX™, is not appropriate in that it does not consider the size and volume of the final product lot.\n\nc. Your firm did not document performance or results of sterility testing of your products that was conducted in-house from January 2021 to March 2022.\n\n4. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, the manufacturing processes for your products have not been validated.\n\n5. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, you have not established appropriate specifications and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\n\n6. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)]. For example, you failed to appropriately test or examine before release for use (b)(4) ((b)(4)) used in your products and the vials that contain the final product.\n\n7. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine the appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. For example, you have assigned two-year expiration dates to your exosome products without supporting data.\n\n8. Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)]. For example, you have not investigated complaints received related to your products, including complaints involving reports of adverse events, in accordance with your written procedures, SOP Q-QC-005, Adverse Events Evaluating and Reporting, Rev. 00, Ver. 00 (Effective Date 01\u002F27\u002F2021) and SOP Q-QA-006, Complaint Investigation, Rev. 1.0 (Effective Date 09\u002F25\u002F2019).\n\n9. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)]. For example:\n\na. You have not maintained batch production records for your in-process conditioned media or for your finished products, including Invitra UC-MSC and Invitra EV-OP, which are manufactured from human umbilical cord tissue.\n\nb. You have not documented the identity of each batch of component or in-process material used, for example the in-process conditioned media used to manufacture your products.\n\n10. Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use [21 CFR 211.63]. For example, incubators used for sterility testing have not been qualified for that use.\n\nWe also note that some of the written procedures collected during the inspection that your firm uses to manufacture Invitra UC-MSC™, Invitra EX™, and Invitra EV-OP™ were identified as “draft.” Your response to this letter should include copies of any revised procedures along with documentation of their implementation.\n\nDuring the inspection, FDA investigators documented that you continued to manufacture and distribute products regulated as drugs and biological products without an approved BLA or an IND in effect for those products (Invitra CBSC Suspension™, Invitra WJ-C™, Invitra WJ-Acellular, Invitra A™, and Invitra AF™) until December 2020, after FDA issued a Warning Letter to your firm in March 2020, notifying you that because those products were not the subject of an approved BLA and because there was not an IND in effect for them, your actions violated the FD&C Act and the PHS Act. The March 2020 Warning Letter also detailed your CGMP violations in the manufacture of those products.\n\nFDA’s March 2020 Warning Letter also notified you that, as a general matter, exosome products intended to treat diseases or conditions in humans are regulated as drugs and biological products and are subject to premarket review and approval requirements. After FDA brought this to your attention, you continued to manufacture and distribute exosome products, including Invitra EX™, and you started manufacturing another exosome product, Invitra EV-OP.\n\nWe acknowledge receipt of your correspondence, dated April 25, 2022, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response and determined that the response is inadequate. You state that you have, “suspended all manufacture of all clinical drug substance and drug product batches at the 20503 Crescent Bay Drive, Lake Forest California facility intended for use in domestic clinical trials.” It is unclear from this statement whether you have suspended manufacture of all products identified in the FDA-483. Further, it is unclear, based on your response, whether you will manufacture your products at any of your other locations for distribution. Your response also describes “interim control[s]” you plan to implement prior to completing certain corrective actions, which suggests that Invitrx will resume manufacturing prior to adequately addressing the existing deficiencies.\n\nAdditionally, we cannot fully assess the adequacy of your responses to many of the observations because they do not provide sufficient detail on the corrective actions you state that you have implemented, lack a timeline for completion of all necessary corrective actions, and fail to provide supporting documentation for your planned corrective actions.\n\nYour response also does not adequately address the failure to have an IND in effect for clinical investigations of your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nWe acknowledge that, in your response, you commit to recall distributed product within expiry after performing a risk assessment. Your response to this letter should include the outcome of this assessment and any subsequent actions.\n\nFinally, during the inspection, your firm described certain products that it manufactures to the FDA investigators as intended for autologous use. However, based on the information obtained during the inspection and included in your correspondence regarding the FDA-483, including information on the customers to whom you are distributing, it is unclear whether these products are also intended for allogeneic use in a first-degree or second-degree blood relative. Please clarify the intended use of these products.\n\nNeither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions may include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed and explain your rationale for your continued manufacture and distribution of products that were the subject of FDA’s March 2020 Warning Letter. We also request that you clarify whether you will continue manufacturing at any of your other locations under the “interim control[s]” described in your response prior to completing all planned corrective actions.\n\nIf you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion.\n\nWe also request your attendance at a Regulatory Meeting to discuss the status of the specific steps you have taken since the inspection to address any violations. We will host the meeting at the FDA Lost Angeles District Office located at 19701 Fairchild, Irvine, CA 92612 on either Tuesday, December 13, 2022, from 9:00am to 10:00am Pacific Time or Wednesday, December 14, 2022, from 10:00am to 11:00am Pacific Time. This meeting will allow you to ask questions and provide FDA with additional information regarding the implementation of your corrective actions. Please contact Amy Graf, Compliance Officer, using the information below, date preference by Tuesday, November 15, 2022. Please provide a list of attendees with title and company name, if other than Invitrx, as well as a list of any questions to ensure the appropriate FDA parties are in attendance, by Wednesday, November 30, 2022.\n\nYour response should be emailed to Amy.Graf@fda.hhs.gov or sent to the following address: Amy Graf, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\ncc:\n\n(b)(4)\n\n______________________\n\n1 Invitrx manufactures human umbilical cord derived cellular products for (b)(4), branded as (b)(4), and (b)(4), branded as (b)(4), using the same manufacturing process used for Invitra UC-MSCTM.\n\nInvitrx manufactures exosome products for (b)(4), branded as (b)(4), and (b)(4), branded as (b)(4), using the same manufacturing process used for Invitra EXTM.","Invitrx Therapeutics, Inc.","invitrx-therapeutics-inc-630712-11092022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finvitrx-therapeutics-inc-630712-11092022","2026-10-26T08:09:00.664874+00:00","Warning Letter","Issued","2022-11-22","630712","Biologics","Division of Biological Products Operations II","Habib Torfi","2026-08-20T01:24:33.889+00:00","VIA UNITED PARCEL SERVICE","2022-11-09",{"id":34,"raw":35,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":24,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":20,"issuing_office":39,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":20,"reference_number":54,"action_taken_date":48,"medical_device_id":20,"response_letter_date":20},1144,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2024-12-03T18:50:00Z\">12\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-03T05:00:00Z\">12\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-therapeutics-inc-696833-12032024\">Applied Therapeutics, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Sponsor","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>24-HFD-45-11-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Shoshana Shendelman, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; Founder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Applied Therapeutics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>545 Fifth Avenue, Suite 1400\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10017\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER&nbsp;\u003C\u002Fstrong>24-HFD-45-11-01\u003C\u002Fp>\n\n\u003Cp>Novermber 27, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Shendelman:&nbsp;\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between April 29 and May 3, 2024. &nbsp;Investigators Kerun Hardeo, Benton M. Ketron, and Cheryl A. Grandinetti, representing FDA, reviewed the role of Applied Therapeutics, Inc. (Applied Therapeutics) as the sponsor of a clinical investigation (Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>.&nbsp;\u003C\u002Fp>\n\n\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigators Hardeo, Ketron, and Grandinetti discussed with you significant findings and presented the Form FDA 483, Inspectional Observations. &nbsp;We acknowledge receipt of your May 9, 2024, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 9, 2024, it appears that Applied Therapeutics did not adhere to the applicable statutory requirements in the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the&nbsp;\u003C\u002Fp>\n\n\u003Cp>Code of Federal Regulations, part 312 (21 CFR 312) governing the conduct of clinical investigations. &nbsp;We wish to emphasize the following:&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>1. Failure to permit an authorized officer or employee of the Food and Drug Administration to have access to and copy and verify records and reports relating to the conduct of a clinical investigation [21 CFR 312.58].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA regulations require sponsors, upon request from an authorized officer or employee of the FDA, at reasonable times, to permit such an officer or employee to have access to and copy and verify any records and reports relating to a clinical investigation. &nbsp;Applied Therapeutics failed to adhere to these requirements. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Applied Therapeutics used Pearson’s Q-global®, a Web-based administration system for capturing data for certain electronic clinical outcome assessments (eCOAs) performed for measuring primary and secondary efficacy endpoints. &nbsp;These eCOAs included the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>FDA requested access to verify electronic data collected and maintained in Q-global® during this inspection and during an earlier inspection conducted at one of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> clinical sites, Site \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.&nbsp;\u003C\u002Fp>\n\n\u003Cp>However, on March 27, 2024, two days after FDA preannounced its inspection of one of the clinical sites, Site \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a third-party vendor contracted by Applied Therapeutics deleted electronic data in Q-global®, including associated audit trails, for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for all 47 subjects enrolled in the study at all \u003Cstrong>(b)(4)\u003C\u002Fstrong> clinical sites. &nbsp;As a result, during the sponsor inspection, FDA was unable to access and copy and verify records and reports relating to the study conducted under Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> specifically certain electronic data collected and maintained in Q-global® for critical eCOAs for all 47 subjects at multiple study timepoints for this clinical investigation. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We acknowledge that this finding, as included on the Form FDA 483 you received, was limited to the deletion of \u003Cstrong>(b)(4)\u003C\u002Fstrong> source data for 11 subjects at Site \u003Cstrong>(b)(4)\u003C\u002Fstrong> and therefore your written response to the Form FDA 483 does not directly address the extent of this finding as discussed in this letter.\u003C\u002Fp>\n\n\u003Cp>In your May 9, 2024, written response, you stated that the deleted \u003Cstrong>(b)(4)\u003C\u002Fstrong> source data for 11 subjects, which was captured directly into Q-global®, could not be recovered in electronic format. &nbsp;You also indicated that steps have been taken to ensure the integrity of the remaining data. &nbsp;For example, you stated that you instructed \u003Cstrong>(b)(4)\u003C\u002Fstrong> (the developers of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to block any further actions regarding data for this study, such that no further data could be deleted. &nbsp;You also stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> transferred a copy of the remainder of the electronic dataset to Applied Therapeutics for backups, and the data is now warehoused with both \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Applied Therapeutics. &nbsp;In addition, you performed an assessment of systems to ensure that the third-party vendor did not have the capability to delete data from any other systems. &nbsp;\u003C\u002Fp>\n\n\u003Cp>You further stated in your May 9, 2024, written response that preventive actions will be taken, including but not limited to the following: &nbsp;\u003C\u002Fp>\n\n\u003Cp>1. For any new trial, Applied Therapeutics will create a data process map that clearly shows the flow and storage of collected data, to ensure that source data is maintained at both the site and at the sponsor.\u003C\u002Fp>\n\n\u003Cp>2. Original paper source documents will remain at the clinical site, with a PDF copy available at the sponsor.\u003C\u002Fp>\n\n\u003Cp>3. Electronic data (even if held on third-party systems) will be backed up appropriately and held at the sponsor.\u003C\u002Fp>\n\n\u003Cp>4. External vendors will not have the ability to delete files from any electronic systems.\u003C\u002Fp>\n\n\u003Cp>5. Appropriate electronic audit trails will be maintained such that any changes to electronic data will be identifiable and auditable.\u003C\u002Fp>\n\n\u003Cp>FDA acknowledges that, in an August 27, 2024, written response to FDA’s August 20, 2024, Information Request, Applied Therapeutics stated that an export of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> data from the backup Q-global® system is maintained with a third-party statistical consulting vendor; however, the data is no longer available in Q-global®. &nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA also acknowledges that, in a September 11, 2024, written response to FDA’s September 5, 2024, correspondence providing the Late Cycle Meeting Background Package, Applied Therapeutics stated that the third-party vendor deleted the data&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> from the Q-global® system without consulting Applied Therapeutics, the sponsor. &nbsp;Applied Therapeutics also stated that it was able to recover this data from the Q-global® system’s backup, except for the 11 \u003Cstrong>(b)(4)\u003C\u002Fstrong> tests. &nbsp;Applied Therapeutics noted that, before the electronic data’s deletion, item-level responses were captured in PDF and in paper copies of the score reports.\u003C\u002Fp>\n\n\u003Cp>While we acknowledge Applied Therapeutics’ response, as well as the corrective and preventive actions that Applied Therapeutics has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. &nbsp;For example, you did not provide sufficient details regarding the procedures being implemented to prevent similar violations in the future. &nbsp;Additionally, we remain concerned that electronic data collected for critical eCOAs was deleted and cannot be verified, which raises concerns about the validity and integrity of the data collected during the clinical investigation. &nbsp;Without access to the pertinent electronic data in Q-global®, including associated audit trails, FDA cannot verify the accuracy, consistency, and completeness of study data collected for critical eCOAs used to measure primary and secondary efficacy endpoints, and cannot evaluate the extent and impact of any reported data errors and discrepancies. &nbsp;FDA also cannot confirm whether the clinical investigation was conducted in compliance with the regulatory responsibilities set forth in 21 CFR 312.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>2. Failure to provide FDA [with] a description and analysis of any other data or information relevant to an evaluation of the safety and effectiveness of the drug product obtained or otherwise received by the applicant from any source, foreign or domestic, including information derived from clinical investigations, including controlled and uncontrolled studies of uses of the drug other than those proposed in the application, commercial marketing experience, reports in the scientific literature, and unpublished scientific papers [21 CFR 314.50(d)(5)(iv)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In order to permit FDA to make a knowledgeable judgment about a new drug application, FDA regulations require applicants for new drug applications to provide FDA with a description and analysis of any data or information relevant to an evaluation of the safety and effectiveness of the drug product obtained or otherwise received by the applicant from any source, including information derived from clinical investigations. &nbsp;Applied Therapeutics, as the applicant of \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to adhere to this requirement. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Specifically, according to Applied Therapeutics’ October 19, 2023, Clinical Study Report for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> which was submitted to FDA on December 28, 2023, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was provided by \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL \u003Cstrong>(b)(4)\u003C\u002Fstrong>.&nbsp;\u003C\u002Fp>\n\n\u003Cp>However, during FDA’s inspection of Site \u003Cstrong>(b)(4)\u003C\u002Fstrong> FDA found that \u003Cstrong>(b)(4)\u003C\u002Fstrong> had supplied the clinical sites for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong> mislabeled as \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL, when in fact the amount of \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplied by \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL. &nbsp;As a result of this error, between March and June 2021, clinical sites administered 80% of the protocol-required dose to subjects. &nbsp;Specifically, at least 19 subjects at Site \u003Cstrong>(b)(4)\u003C\u002Fstrong> received a lower dosage of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> than the protocol required. &nbsp;On June 17, 2021, Applied Therapeutics notified clinical sites of this error, and on June 29, 2021, clinical sites were provided with a new formulation of the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> at the correct concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL. &nbsp;Clinical sites were also provided with an updated version of the pharmacy manual, with instructions on drug administration. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Applied Therapeutics failed to provide FDA with any description or analysis of the information describing the nature and extent of the dosing errors related to the mislabeled \u003Cstrong>(b)(4)\u003C\u002Fstrong>. &nbsp;Specifically, Applied Therapeutics reported dose levels for subjects as stated in the protocol (for example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Fkg), rather than the actual dose levels administered. &nbsp;Information on the nature and extent of the dosing errors is relevant to an evaluation of the safety and effectiveness of the investigational drug product. &nbsp;Therefore, Applied Therapeutics failed to provide sufficient information at the time of submission of the application to enable FDA to make an informed decision regarding the impact of the dosing-error incident on study data. &nbsp;This failure raises significant concerns about the validity, reliability, and integrity of the data for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>. &nbsp;Furthermore, Applied Therapeutics’ failure to disclose this critical information raises significant concerns about the sponsor’s oversight and conduct of clinical investigations, including its compliance with the reporting requirements for human drug products.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that this finding was not included on the Form FDA 483 you received, and therefore your written response does not address this finding.\u003C\u002Fp>\n\n\u003Cp>We emphasize that as a sponsor, Applied Therapeutics has ultimate oversight of the clinical investigation, and was responsible for ensuring compliance with all applicable FDA regulations governing the conduct of clinical investigations. &nbsp;Applied Therapeutics’ failure to permit FDA access to verify records and reports related to a clinical investigation, and its failure to provide FDA information relevant to an evaluation of the safety and effectiveness of an \u003Cstrong>(b)(4)\u003C\u002Fstrong> raise significant concerns about the validity and reliability of data collected for this clinical investigation.&nbsp;\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all inclusive list of deficiencies with your clinical study of an \u003Cstrong>(b)(4)\u003C\u002Fstrong>. &nbsp;As the sponsor, it is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. &nbsp;You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. &nbsp;Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. &nbsp;Failure to address this matter adequately may lead to regulatory action. &nbsp;If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Should you have any questions or concerns regarding this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. &nbsp;Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Brittany L. Garr-Colón, MPH\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352&nbsp;&nbsp; &nbsp;\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD &nbsp;20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nDavid C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed\u003Cbr>\nelectronically. Following this are manifestations of any and all\u003Cbr>\nelectronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nDAVID C BURROW\u003Cbr>\n11\u002F27\u002F2024 09:09:23 AM\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n24-HFD-45-11-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nShoshana Shendelman, Ph.D.\n\nRecipient Title\n\nCEO & Founder\n\nApplied Therapeutics, Inc.\n\n545 Fifth Avenue, Suite 1400\n\nNew York, NY 10017\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER 24-HFD-45-11-01\n\nNovermber 27, 2024\n\nDear Dr. Shendelman:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between April 29 and May 3, 2024. Investigators Kerun Hardeo, Benton M. Ketron, and Cheryl A. Grandinetti, representing FDA, reviewed the role of Applied Therapeutics, Inc. (Applied Therapeutics) as the sponsor of a clinical investigation (Protocol (b)(4).\n\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigators Hardeo, Ketron, and Grandinetti discussed with you significant findings and presented the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 9, 2024, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 9, 2024, it appears that Applied Therapeutics did not adhere to the applicable statutory requirements in the Federal Food, Drug and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the\n\nCode of Federal Regulations, part 312 (21 CFR 312) governing the conduct of clinical investigations. We wish to emphasize the following:\n\n1. Failure to permit an authorized officer or employee of the Food and Drug Administration to have access to and copy and verify records and reports relating to the conduct of a clinical investigation [21 CFR 312.58].\n\nFDA regulations require sponsors, upon request from an authorized officer or employee of the FDA, at reasonable times, to permit such an officer or employee to have access to and copy and verify any records and reports relating to a clinical investigation. Applied Therapeutics failed to adhere to these requirements.\n\nSpecifically, for Protocol (b)(4), Applied Therapeutics used Pearson’s Q-global®, a Web-based administration system for capturing data for certain electronic clinical outcome assessments (eCOAs) performed for measuring primary and secondary efficacy endpoints. These eCOAs included the (b)(4).\n\nFDA requested access to verify electronic data collected and maintained in Q-global® during this inspection and during an earlier inspection conducted at one of the (b)(4) clinical sites, Site (b)(4) between (b)(4) and (b)(4).\n\nHowever, on March 27, 2024, two days after FDA preannounced its inspection of one of the clinical sites, Site (b)(4), a third-party vendor contracted by Applied Therapeutics deleted electronic data in Q-global®, including associated audit trails, for the (b)(4) for all 47 subjects enrolled in the study at all (b)(4) clinical sites. As a result, during the sponsor inspection, FDA was unable to access and copy and verify records and reports relating to the study conducted under Protocol (b)(4) specifically certain electronic data collected and maintained in Q-global® for critical eCOAs for all 47 subjects at multiple study timepoints for this clinical investigation.\n\nWe acknowledge that this finding, as included on the Form FDA 483 you received, was limited to the deletion of (b)(4) source data for 11 subjects at Site (b)(4) and therefore your written response to the Form FDA 483 does not directly address the extent of this finding as discussed in this letter.\n\nIn your May 9, 2024, written response, you stated that the deleted (b)(4) source data for 11 subjects, which was captured directly into Q-global®, could not be recovered in electronic format. You also indicated that steps have been taken to ensure the integrity of the remaining data. For example, you stated that you instructed (b)(4) (the developers of (b)(4) to block any further actions regarding data for this study, such that no further data could be deleted. You also stated that (b)(4) transferred a copy of the remainder of the electronic dataset to Applied Therapeutics for backups, and the data is now warehoused with both (b)(4) and Applied Therapeutics. In addition, you performed an assessment of systems to ensure that the third-party vendor did not have the capability to delete data from any other systems.\n\nYou further stated in your May 9, 2024, written response that preventive actions will be taken, including but not limited to the following:\n\n1. For any new trial, Applied Therapeutics will create a data process map that clearly shows the flow and storage of collected data, to ensure that source data is maintained at both the site and at the sponsor.\n\n2. Original paper source documents will remain at the clinical site, with a PDF copy available at the sponsor.\n\n3. Electronic data (even if held on third-party systems) will be backed up appropriately and held at the sponsor.\n\n4. External vendors will not have the ability to delete files from any electronic systems.\n\n5. Appropriate electronic audit trails will be maintained such that any changes to electronic data will be identifiable and auditable.\n\nFDA acknowledges that, in an August 27, 2024, written response to FDA’s August 20, 2024, Information Request, Applied Therapeutics stated that an export of the (b)(4) data from the backup Q-global® system is maintained with a third-party statistical consulting vendor; however, the data is no longer available in Q-global®.\n\nFDA also acknowledges that, in a September 11, 2024, written response to FDA’s September 5, 2024, correspondence providing the Late Cycle Meeting Background Package, Applied Therapeutics stated that the third-party vendor deleted the data (b)(4) from the Q-global® system without consulting Applied Therapeutics, the sponsor. Applied Therapeutics also stated that it was able to recover this data from the Q-global® system’s backup, except for the 11 (b)(4) tests. Applied Therapeutics noted that, before the electronic data’s deletion, item-level responses were captured in PDF and in paper copies of the score reports.\n\nWhile we acknowledge Applied Therapeutics’ response, as well as the corrective and preventive actions that Applied Therapeutics has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, you did not provide sufficient details regarding the procedures being implemented to prevent similar violations in the future. Additionally, we remain concerned that electronic data collected for critical eCOAs was deleted and cannot be verified, which raises concerns about the validity and integrity of the data collected during the clinical investigation. Without access to the pertinent electronic data in Q-global®, including associated audit trails, FDA cannot verify the accuracy, consistency, and completeness of study data collected for critical eCOAs used to measure primary and secondary efficacy endpoints, and cannot evaluate the extent and impact of any reported data errors and discrepancies. FDA also cannot confirm whether the clinical investigation was conducted in compliance with the regulatory responsibilities set forth in 21 CFR 312.\n\n2. Failure to provide FDA [with] a description and analysis of any other data or information relevant to an evaluation of the safety and effectiveness of the drug product obtained or otherwise received by the applicant from any source, foreign or domestic, including information derived from clinical investigations, including controlled and uncontrolled studies of uses of the drug other than those proposed in the application, commercial marketing experience, reports in the scientific literature, and unpublished scientific papers [21 CFR 314.50(d)(5)(iv)].\n\nIn order to permit FDA to make a knowledgeable judgment about a new drug application, FDA regulations require applicants for new drug applications to provide FDA with a description and analysis of any data or information relevant to an evaluation of the safety and effectiveness of the drug product obtained or otherwise received by the applicant from any source, including information derived from clinical investigations. Applied Therapeutics, as the applicant of (b)(4) failed to adhere to this requirement.\n\nSpecifically, according to Applied Therapeutics’ October 19, 2023, Clinical Study Report for Protocol (b)(4) which was submitted to FDA on December 28, 2023, the (b)(4) was provided by (b)(4) as a (b)(4) mg\u002FmL (b)(4).\n\nHowever, during FDA’s inspection of Site (b)(4) FDA found that (b)(4) had supplied the clinical sites for Protocol (b)(4) with (b)(4) mislabeled as (b)(4) mg\u002FmL, when in fact the amount of (b)(4) supplied by (b)(4) was (b)(4) mg\u002FmL. As a result of this error, between March and June 2021, clinical sites administered 80% of the protocol-required dose to subjects. Specifically, at least 19 subjects at Site (b)(4) received a lower dosage of the (b)(4) than the protocol required. On June 17, 2021, Applied Therapeutics notified clinical sites of this error, and on June 29, 2021, clinical sites were provided with a new formulation of the (b)(4) at the correct concentration of (b)(4) mg\u002FmL. Clinical sites were also provided with an updated version of the pharmacy manual, with instructions on drug administration.\n\nApplied Therapeutics failed to provide FDA with any description or analysis of the information describing the nature and extent of the dosing errors related to the mislabeled (b)(4). Specifically, Applied Therapeutics reported dose levels for subjects as stated in the protocol (for example, (b)(4) mg\u002Fkg), rather than the actual dose levels administered. Information on the nature and extent of the dosing errors is relevant to an evaluation of the safety and effectiveness of the investigational drug product. Therefore, Applied Therapeutics failed to provide sufficient information at the time of submission of the application to enable FDA to make an informed decision regarding the impact of the dosing-error incident on study data. This failure raises significant concerns about the validity, reliability, and integrity of the data for Protocol (b)(4). Furthermore, Applied Therapeutics’ failure to disclose this critical information raises significant concerns about the sponsor’s oversight and conduct of clinical investigations, including its compliance with the reporting requirements for human drug products.\n\nWe acknowledge that this finding was not included on the Form FDA 483 you received, and therefore your written response does not address this finding.\n\nWe emphasize that as a sponsor, Applied Therapeutics has ultimate oversight of the clinical investigation, and was responsible for ensuring compliance with all applicable FDA regulations governing the conduct of clinical investigations. Applied Therapeutics’ failure to permit FDA access to verify records and reports related to a clinical investigation, and its failure to provide FDA information relevant to an evaluation of the safety and effectiveness of an (b)(4) raise significant concerns about the validity and reliability of data collected for this clinical investigation.\n\nThis letter is not intended to be an all inclusive list of deficiencies with your clinical study of an (b)(4). As the sponsor, it is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\n\nShould you have any questions or concerns regarding this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\n\nBrittany L. Garr-Colón, MPH\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n{See appended electronic signature page}\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed\n\nelectronically. Following this are manifestations of any and all\n\nelectronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nDAVID C BURROW\n\n11\u002F27\u002F2024 09:09:23 AM","Applied Therapeutics, Inc.","applied-therapeutics-inc-696833-12032024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-therapeutics-inc-696833-12032024","2026-10-26T08:07:56.904785+00:00","2024-12-03","696833","Drugs","Shoshana Shendelman, Ph.D.","2026-08-19T17:40:17.936+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","24-HFD-45-11-01",{"id":56,"raw":57,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":45,"fei_number":20,"letter_url":67,"updated_at":68,"action_type":23,"case_status":24,"posted_date":69,"marcs_cms_no":70,"product_type":27,"closeout_date":20,"issuing_office":61,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":20,"reference_number":74,"action_taken_date":75,"medical_device_id":20,"response_letter_date":20},1296,[58,59,60,61,62,13,13,13],"\u003Ctime datetime=\"2024-08-27T13:20:00Z\">08\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-26T04:00:00Z\">07\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcarsgen-therapeutics-corporation-686504-07262024\">CARsgen Therapeutics Corporation\u003C\u002Fa>","Center for Biologics Evaluation and Research","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 24-686504\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Zonghai Li, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CARsgen Therapeutics Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4022 Stirrup Creek Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Durham\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27703\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:zonghaili@carsgen.com\"> zonghaili@carsgen.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 26, 2024\u003C\u002Fp>\n\n\u003Cp>CBER 24-686504\u003Cbr>\n\u003Cbr>\nDear Dr. Li:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility located at the above address between November 28, 2023, and December 6, 2023. During the inspection, FDA documented significant violations of current good manufacturing practice (CGMP) requirements, including requirements in 21 CFR parts 210 and 211, in the manufacture of your investigational new drugs and biological products, Fully Human Anti-BCMA (B-Cell Maturation Antigen) Autologous CAR T Cell (CT053; CAR-BCMA T Cells) and Humanized Anti-claudin 18.2 Autologous CAR T Cells (CT041; CAR-CLDN18.2 T Cells) (collectively, “your products”). Your products have been made available for use in a Phase 2 study, as described in 21 CFR 312.21(b).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 351(a)(2)(B). It is a prohibited act under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k), to do any act with respect to a drug that results in the drug being adulterated, while held for sale after shipment of the drug or one or more of its components in interstate commerce. Your causing your products to be adulterated within the meaning of 501(a)(2)(B) of the FD&amp;C Act, while your products are held for sale after shipment in interstate commerce of one or more of their components, is a prohibited act under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k). Further, it is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C.§ 331(a) to cause the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded. Your causing of your products to be introduced or delivered for introduction into interstate commerce is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003Cbr>\n\u003Cbr>\nAt the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form 483), documenting significant CGMP violations observed during the inspection. The CGMP violations applicable to your products include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition and to keep them free of infestation by rodents, birds, insects, and other vermin. Trash and organic waste matter shall be held and disposed of in a timely and sanitary manner. [21 CFR 211.56(a)].\u003C\u002Fstrong> Specifically, on July 14, 2023, your Quality Assurance team observed a box of food from June 16, 2023, covered in scuttle fly pupae in the mechanical room which houses the air handling units and failed to remove the box of food until July 31, 2023. After this event, scuttle fly larvae were found in ten environmental and personnel monitoring samples collected in the cleanrooms in July 2023. Additionally, on July 26, 2023, in Suite \u003Cstrong>(b)(4)\u003C\u002Fstrong> Clean Room \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Grade \u003Cstrong>(b)(4)\u003C\u002Fstrong>) a living scuttle fly was observed on the tube rack. Adequate control of insect infestation is needed to ensure product quality and safety.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate system for preventing contamination and monitoring environmental conditions in aseptic processing areas. [21 CFR 211.42(c)(10)(iv)]. Your firm also failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile. [21 CFR 211.113(b)].\u003C\u002Fstrong> For example,\u003C\u002Fp>\n\n\u003Cp>a. Non-viable particulate monitoring is not being conducted during open manufacturing manipulations within the Grade \u003Cstrong>(b)(4)\u003C\u002Fstrong> utilized as the aseptic processing area for production of Humanized Anti-claudin 18.2 Autologous CAR T Cells (CT041). Non-viable particulate monitoring is critical for the detection of particulates in the manufacturing area as they pose patient harm for products administered intravenously as microorganisms can travel on particulates to contaminate the product.\u003C\u002Fp>\n\n\u003Cp>b. Viable microbial active air monitoring is not being conducted during open manufacturing manipulations within the Grade \u003Cstrong>(b)(4)\u003C\u002Fstrong> utilized as the aseptic processing area for production of your products. Viable microbial active air monitoring is important for the detection of microorganisms in the environment surrounding the product that is exposed to the manufacturing environment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions. [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example, you have not validated the cleaning process for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the production of your products purported to be sterile. Your Senior Vice President of Quality stated that your firm has not conducted a cleaning validation to ascertain that your cleaning process for manufacturing your products can adequately remove contamination from your manufacturing equipment and cleanroom. Cleaning validation is used to establish cleaning conditions effective against the removal of microorganisms commonly found in your manufacturing environment that pose a contamination risk to your sterile products.\u003C\u002Fp>\n\n\u003Cp>Your responses dated December 28, 2023, March 1, 2024, April 15, 2024 and May 23, 2024, are acknowledged. Your cleaning gap assessment, cleaning validation protocol and revisions to SOPs have been reviewed. While you indicate the cleaning program will assess the effective removal of bacteria and fungi from surfaces through a disinfectant efficacy study, you have failed to provide any results from this study. Without this information, it is unclear whether your disinfection process is effective for the removal of microorganisms that may contaminate your product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess. [21 CFR 211.100(a)].\u003C\u002Fstrong> For example, there was no procedure for 100% visual inspection of the final drug product to ensure that it is essentially free from visible particulates, which is necessary to ensure quality and purity prior to intravascular administration.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch had already been distributed. [21 CFR 211.192].\u003C\u002Fstrong> For example, there were excursions of the action limit associated with microbial monitoring of personnel in the Grade \u003Cstrong>(b)(4)\u003C\u002Fstrong> environment where your products are manufactured. During the investigation of these excursions, CAPAs were proposed but never implemented. Since that time, additional excursions for microbial monitoring of personnel action limit within Grade \u003Cstrong>(b)(4)\u003C\u002Fstrong> during manufacturing of your products have occurred. Your products have been released following these excursions. Appropriate CAPAs are to be identified and implemented in a timely manner to prevent recurrence of excursions.\u003C\u002Fp>\n\n\u003Cp>It is noted in your response dated April 15, 2024, that “CARsgen RTP site Deviation and CAPA SOPs (NC-SOP-QA-0006, NC-SOP-QA-0007 respectively)” became effective on January 31, 2024. Appropriate control mechanisms have been added to the CAPA SOP to ensure both implementation of CAPAs and verification of effectiveness checks are in place.” However, the updated SOPs have not been provided for review to determine suitability of the response in addressing this violation and providing for appropriate corrective action.\u003C\u002Fp>\n\n\u003Cp>The nature of your above-listed violations demonstrates that you have failed to ensure that your firm manufactures drug products that meet established specifications for identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your correspondences dated December 28, 2023, March 1, 2024, April 15, 2024, and May 23, 2024, which respond to the Form FDA-483 and set forth your corrective actions. We acknowledge you have paused manufacturing your products as of December 12, 2023, notified clinics not to administer previously released drug products to patients, and have plans for disposition of products that remain in your control. As noted above in response to specific violations, you have not provided sufficient detail to assess the adequacy of your proposed corrective actions; for all other violations, FDA may need to verify your proposed corrective actions during an inspection of your facility.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form 483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of violations that may exist at your facility. It is your responsibility to ensure full compliance with applicable requirements in the FD&amp;C Act, Public Health Service Act (PHS Act), and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may result in regulatory action without further notice. Such actions may include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 24-686504\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nZonghai Li, M.D.\n\nRecipient Title\n\nChief Executive Officer\n\nCARsgen Therapeutics Corporation\n\n4022 Stirrup Creek Drive\n\nDurham, NC 27703\n\nUnited States\n\nzonghaili@carsgen.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\n\nJuly 26, 2024\n\nCBER 24-686504\n\nDear Dr. Li:\n\nThe United States Food and Drug Administration (FDA) inspected your facility located at the above address between November 28, 2023, and December 6, 2023. During the inspection, FDA documented significant violations of current good manufacturing practice (CGMP) requirements, including requirements in 21 CFR parts 210 and 211, in the manufacture of your investigational new drugs and biological products, Fully Human Anti-BCMA (B-Cell Maturation Antigen) Autologous CAR T Cell (CT053; CAR-BCMA T Cells) and Humanized Anti-claudin 18.2 Autologous CAR T Cells (CT041; CAR-CLDN18.2 T Cells) (collectively, “your products”). Your products have been made available for use in a Phase 2 study, as described in 21 CFR 312.21(b).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 351(a)(2)(B). It is a prohibited act under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k), to do any act with respect to a drug that results in the drug being adulterated, while held for sale after shipment of the drug or one or more of its components in interstate commerce. Your causing your products to be adulterated within the meaning of 501(a)(2)(B) of the FD&C Act, while your products are held for sale after shipment in interstate commerce of one or more of their components, is a prohibited act under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k). Further, it is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C.§ 331(a) to cause the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded. Your causing of your products to be introduced or delivered for introduction into interstate commerce is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\n\nAt the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form 483), documenting significant CGMP violations observed during the inspection. The CGMP violations applicable to your products include, but are not limited to, the following:\n\n1. Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition and to keep them free of infestation by rodents, birds, insects, and other vermin. Trash and organic waste matter shall be held and disposed of in a timely and sanitary manner. [21 CFR 211.56(a)]. Specifically, on July 14, 2023, your Quality Assurance team observed a box of food from June 16, 2023, covered in scuttle fly pupae in the mechanical room which houses the air handling units and failed to remove the box of food until July 31, 2023. After this event, scuttle fly larvae were found in ten environmental and personnel monitoring samples collected in the cleanrooms in July 2023. Additionally, on July 26, 2023, in Suite (b)(4) Clean Room (b)(4) (Grade (b)(4)) a living scuttle fly was observed on the tube rack. Adequate control of insect infestation is needed to ensure product quality and safety.\n\n2. Your firm failed to establish an adequate system for preventing contamination and monitoring environmental conditions in aseptic processing areas. [21 CFR 211.42(c)(10)(iv)]. Your firm also failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile. [21 CFR 211.113(b)]. For example,\n\na. Non-viable particulate monitoring is not being conducted during open manufacturing manipulations within the Grade (b)(4) utilized as the aseptic processing area for production of Humanized Anti-claudin 18.2 Autologous CAR T Cells (CT041). Non-viable particulate monitoring is critical for the detection of particulates in the manufacturing area as they pose patient harm for products administered intravenously as microorganisms can travel on particulates to contaminate the product.\n\nb. Viable microbial active air monitoring is not being conducted during open manufacturing manipulations within the Grade (b)(4) utilized as the aseptic processing area for production of your products. Viable microbial active air monitoring is important for the detection of microorganisms in the environment surrounding the product that is exposed to the manufacturing environment.\n\n3. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions. [21 CFR 211.42(c)(10)(v)]. For example, you have not validated the cleaning process for the (b)(4) used in the production of your products purported to be sterile. Your Senior Vice President of Quality stated that your firm has not conducted a cleaning validation to ascertain that your cleaning process for manufacturing your products can adequately remove contamination from your manufacturing equipment and cleanroom. Cleaning validation is used to establish cleaning conditions effective against the removal of microorganisms commonly found in your manufacturing environment that pose a contamination risk to your sterile products.\n\nYour responses dated December 28, 2023, March 1, 2024, April 15, 2024 and May 23, 2024, are acknowledged. Your cleaning gap assessment, cleaning validation protocol and revisions to SOPs have been reviewed. While you indicate the cleaning program will assess the effective removal of bacteria and fungi from surfaces through a disinfectant efficacy study, you have failed to provide any results from this study. Without this information, it is unclear whether your disinfection process is effective for the removal of microorganisms that may contaminate your product.\n\n4. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess. [21 CFR 211.100(a)]. For example, there was no procedure for 100% visual inspection of the final drug product to ensure that it is essentially free from visible particulates, which is necessary to ensure quality and purity prior to intravascular administration.\n\n5. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch had already been distributed. [21 CFR 211.192]. For example, there were excursions of the action limit associated with microbial monitoring of personnel in the Grade (b)(4) environment where your products are manufactured. During the investigation of these excursions, CAPAs were proposed but never implemented. Since that time, additional excursions for microbial monitoring of personnel action limit within Grade (b)(4) during manufacturing of your products have occurred. Your products have been released following these excursions. Appropriate CAPAs are to be identified and implemented in a timely manner to prevent recurrence of excursions.\n\nIt is noted in your response dated April 15, 2024, that “CARsgen RTP site Deviation and CAPA SOPs (NC-SOP-QA-0006, NC-SOP-QA-0007 respectively)” became effective on January 31, 2024. Appropriate control mechanisms have been added to the CAPA SOP to ensure both implementation of CAPAs and verification of effectiveness checks are in place.” However, the updated SOPs have not been provided for review to determine suitability of the response in addressing this violation and providing for appropriate corrective action.\n\nThe nature of your above-listed violations demonstrates that you have failed to ensure that your firm manufactures drug products that meet established specifications for identity, strength, quality, and purity.\n\nWe have reviewed your correspondences dated December 28, 2023, March 1, 2024, April 15, 2024, and May 23, 2024, which respond to the Form FDA-483 and set forth your corrective actions. We acknowledge you have paused manufacturing your products as of December 12, 2023, notified clinics not to administer previously released drug products to patients, and have plans for disposition of products that remain in your control. As noted above in response to specific violations, you have not provided sufficient detail to assess the adequacy of your proposed corrective actions; for all other violations, FDA may need to verify your proposed corrective actions during an inspection of your facility.\n\nNeither this letter nor the observations noted on the Form 483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of violations that may exist at your facility. It is your responsibility to ensure full compliance with applicable requirements in the FD&C Act, Public Health Service Act (PHS Act), and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may result in regulatory action without further notice. Such actions may include seizure and\u002For injunction.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\n\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector\n\nOffice of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research","CARsgen Therapeutics Corporation","carsgen-therapeutics-corporation-686504-07262024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcarsgen-therapeutics-corporation-686504-07262024","2026-10-26T08:08:11.812832+00:00","2024-08-27","686504","Zonghai Li, M.D.","2026-08-19T23:52:12.565+00:00","Via UPS and EMAIL","CBER 24-686504","2024-07-26",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":20,"letter_url":89,"updated_at":90,"action_type":23,"case_status":24,"posted_date":91,"marcs_cms_no":92,"product_type":27,"closeout_date":20,"issuing_office":82,"recipient_name":93,"body_fetched_at":94,"delivery_method":73,"recipient_title":20,"reference_number":95,"action_taken_date":96,"medical_device_id":20,"response_letter_date":20},540,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2025-10-14T04:00:00Z\">10\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-30T04:00:00Z\">09\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fallovate-therapeutics-llc-708912-09302025\">Allovate Therapeutics, LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","CGMP\u002FDeviations\u002FBiologics License Application (BLA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-708912\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William Reisacher, MD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Scientific Advisor and Co-Founder \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Allovate Therapeutics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>20 W 125th St #1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10027\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:wir2011@med.cornell.edu\"> wir2011@med.cornell.edu\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 30, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25-708912\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Reisacher:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your brochure at https:\u002F\u002Fent.weill.cornell.edu\u002Fsites\u002Fdefault\u002Ffiles\u002Flifewithoutallergies.pdf (last visited September 2025), which describes Allerdent, an allergenic toothpaste, which you state “can be sent directly to your home,” (hereafter, “your product”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> This letter is to advise you that your product is an unapproved new drug in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your product is also an unlicensed biological product in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. The introduction or delivery for introduction of your product into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information reviewed by FDA, https:\u002F\u002Fent.weill.cornell.edu\u002Fsites\u002Fdefault\u002Ffiles\u002Flifewithoutallergies.pdf (last visited September 2025), your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For is intended to affect the structure or function of the body. For example, your brochure states, “With Allerdent you can experience allergy immunotherapy while simply brushing your teeth every day. This is known as oral mucosal immunotherapy, or OMIT”.\u003C\u002Fp>\u003Cp>Therefore, your product is a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We also reviewed the website http:\u002F\u002Fallovate.com, which directs to http:\u002F\u002Feasily healthcare.com (last visited September 2025). The Easily Healthcare website offers Easily Allergy Toothpaste, an allergenic toothpaste, for sale.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 25-708912\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nWilliam Reisacher, MD\n\nRecipient Title\n\nSenior Scientific Advisor and Co-Founder\n\nAllovate Therapeutics, LLC\n\n20 W 125th St #1\n\nNew York, NY 10027\n\nUnited States\n\nwir2011@med.cornell.edu\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nSeptember 30, 2025\nCBER 25-708912\nDear Dr. Reisacher:\nThe United States Food and Drug Administration (FDA) reviewed your brochure at https:\u002F\u002Fent.weill.cornell.edu\u002Fsites\u002Fdefault\u002Ffiles\u002Flifewithoutallergies.pdf (last visited September 2025), which describes Allerdent, an allergenic toothpaste, which you state “can be sent directly to your home,” (hereafter, “your product”).1 This letter is to advise you that your product is an unapproved new drug in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your product is also an unlicensed biological product in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. The introduction or delivery for introduction of your product into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information reviewed by FDA, https:\u002F\u002Fent.weill.cornell.edu\u002Fsites\u002Fdefault\u002Ffiles\u002Flifewithoutallergies.pdf (last visited September 2025), your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For is intended to affect the structure or function of the body. For example, your brochure states, “With Allerdent you can experience allergy immunotherapy while simply brushing your teeth every day. This is known as oral mucosal immunotherapy, or OMIT”.\nTherefore, your product is a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n________________________\n1 We also reviewed the website http:\u002F\u002Fallovate.com, which directs to http:\u002F\u002Feasily healthcare.com (last visited September 2025). The Easily Healthcare website offers Easily Allergy Toothpaste, an allergenic toothpaste, for sale.","Allovate Therapeutics, LLC","allovate-therapeutics-llc-708912-09302025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fallovate-therapeutics-llc-708912-09302025","2026-10-26T08:07:52.709929+00:00","2025-10-14","708912","William Reisacher, MD","2026-08-19T16:14:15.497+00:00","CBER 25-708912","2025-09-30",{"id":98,"raw":99,"subject":104,"body_html":105,"body_text":106,"firm_name":107,"letter_id":108,"created_at":109,"fei_number":20,"letter_url":110,"updated_at":111,"action_type":23,"case_status":24,"posted_date":112,"marcs_cms_no":113,"product_type":27,"closeout_date":20,"issuing_office":103,"recipient_name":114,"body_fetched_at":115,"delivery_method":116,"recipient_title":20,"reference_number":20,"action_taken_date":117,"medical_device_id":20,"response_letter_date":20},436,[100,101,102,103,104,13,13,13],"\u003Ctime datetime=\"2025-12-09T05:00:00Z\">12\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-25T05:00:00Z\">11\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flux-therapeutics-llc-dba-ponya-therapeutics-llc-720001-11252025\">Lux Therapeutics LLC dba Ponya Therapeutics LLC\u003C\u002Fa>","Office of Compliance and Biologics Quality","Unapproved New Drug\u002FUnlicensed Biological Product\u002FBiologics License Application (BLA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>Signature Required\n                                                                          \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mekonnen Abebe\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lux Therapeutics LLC dba Ponya Therapeutics LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13 Corporate Blvd NE\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brookhaven\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30329\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:MAbebe@ponyadx.com\"> MAbebe@ponyadx.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Compliance and Biologics Quality\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CBER 26-720001\u003C\u002Fp>\u003Cp>November 25, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Abebe:\u003C\u002Fp>\u003Cp>During an inspection of your firm, Lux Therapeutics LLC dba Ponya Therapeutics LLC located at 13 Corporate Blvd NE, Brookhaven, GA, conducted between June 2, 2025, and June 6, 2025, the United States Food and Drug Administration (FDA) documented significant violations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (21 CFR) Part 1271 (21 CFR 1271) and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\u003Ca id=\"footnoteref1_prtg1x6\" href=\"#footnote1_prtg1x6\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>The observations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection, and following FDA’s review, your violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1) Failure to validate and approve a process according to established procedures where the results of processing cannot be fully verified by subsequent inspections and tests. The validation activities and results must be documented, including the date and signature of the individual(s) approving the validation [21 CFR 1271.230(a)]. For example, you failed to validate the manufacturing process for your dehydrated, dual layer amniotic membrane patch, TheraMend, which cannot be fully verified, to ensure that your process does not cause contamination or cross-contamination and prevents the introduction, transmission or spread of communicable disease through the use of the HCT\u002FP. Since August 2023, your firm has processed TheraMend products and distributed those products without a validated process.\u003C\u002Fp>\u003Cp>2) Failure to provide a summary of records to accompany an HCT\u002FP, that contains a listing and interpretation of the results of all communicable disease tests performed [21 CFR 1271.55(b)(2)]. Specifically, a listing and interpretation of the results of all communicable disease tests is not included on the \u003Cem>Notification of Requirements to Maintain Traceability of Human Tissue-Based Products or Instructions for Use and Product Information\u003C\u002Fem> forms, which are considered accompanying records as described in 21 CFR 1271.55(a).\u003C\u002Fp>\u003Cp>The violations identified above are not intended to be an all-inclusive list of violations at your facility. It is your responsibility to ensure that your establishment complies with all applicable federal regulations. You are responsible for reviewing your firm’s operations, including firms within the same organization, as a whole to ensure that you are in compliance with the law.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your email correspondence submitted on June 30, 2025, responding to the inspectional observations. We have reviewed your response, and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response:\u003C\u002Fp>\u003Cp>• In response to Observation 1, you state that you discontinued manufacturing your Luxegen product, derived from human umbilical cord tissue, but will continue distributing Luxegen until December 1, 2025. We remain concerned about the Luxegen product that you previously distributed as well as your continued distribution of this product given its lack of approval as well as the conditions under which it was manufactured, as described in the FDA-483. We ask that you respond to this letter with your plans for addressing the Luxegen product that remains in the marketplace, within expiry, as well as confirmation that you have ceased distribution by December 1, 2025, and documentation demonstrating that you have done so.\u003C\u002Fp>\u003Cp>• In response to Observation 4a, you stated “Validation planning will being [sic] in July 2025 with all process validation activities anticipated to be completed by the end of Q2 2026.” Your response does not indicate that you will halt distribution of TheraMend products until your process has been validated. Your response also does not indicate any planned actions for the TheraMend products that have already been distributed.\u003C\u002Fp>\u003Cp>Additionally, your response states, “Regarding product in the field, to date, we have not received any product complaints or adverse events. Similarly, the product has a straightforward manufacturing process, and an approximately 99.99% change of passing validation. It is intended as a protective covering, so we believe any product in the field is safe and of a quality manner.” This justification is insufficient. You are required to validate your process to ensure that processing prevents the introduction, transmission, or spread of communicable disease through use of the HCT\u002FP. It is your responsibility to ensure you validate all processing activities for the product(s) you are manufacturing.\u003C\u002Fp>\u003Cp>• In response to Observation 7, we acknowledge your commitment to revise procedures and retrain staff on the required summary of records as part of your CAPA #CPAR25-010. Please also ensure that a statement whether, based on the results of screening and testing, the donor has been determined to be eligible or ineligible accompanies your HCT\u002FP at all times once a donor-eligibility determination has been made in accordance with 21 CFR 1271.55(a)(2).\u003C\u002Fp>\u003Cp>You should take prompt action to correct any violations addressed in this letter and prevent their recurrence. Failure to promptly correct any violations may result in regulatory action being initiated by FDA without further notice.\u003C\u002Fp>\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent them, or similar violations, from occurring again. Additionally, include any documentation necessary to show that correction has been achieved. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\u003C\u002Fp>\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>If you have any questions regarding this letter, please contact CBER’s Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Please be advised that only written communications are considered official.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality&nbsp;\u003Cbr>Center for Biologics Evaluation and Research&nbsp;\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_prtg1x6\">\u003Ca href=\"#footnoteref1_prtg1x6\">1\u003C\u002Fa>This letter only pertains to your dehydrated, dual layer amniotic membrane patch products, TheraMend, intended to serve as a covering or barrier. Accordingly, references in this letter to HCT\u002FPs or “products” do not include products manufactured by your firm that are not regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not address those products.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nSignature Required\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMekonnen Abebe\n\nRecipient Title\n\nOwner and Chief Executive Officer\n\nLux Therapeutics LLC dba Ponya Therapeutics LLC\n\n13 Corporate Blvd NE\n\nBrookhaven, GA 30329\n\nUnited States\n\nMAbebe@ponyadx.com\n\nIssuing Office:\n\nOffice of Compliance and Biologics Quality\n\nUnited States\n\nWARNING LETTER\nCBER 26-720001\nNovember 25, 2025\nDear Mr. Abebe:\nDuring an inspection of your firm, Lux Therapeutics LLC dba Ponya Therapeutics LLC located at 13 Corporate Blvd NE, Brookhaven, GA, conducted between June 2, 2025, and June 6, 2025, the United States Food and Drug Administration (FDA) documented significant violations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (21 CFR) Part 1271 (21 CFR 1271) and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].1\nThe observations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection, and following FDA’s review, your violations include, but are not limited to, the following:\n1) Failure to validate and approve a process according to established procedures where the results of processing cannot be fully verified by subsequent inspections and tests. The validation activities and results must be documented, including the date and signature of the individual(s) approving the validation [21 CFR 1271.230(a)]. For example, you failed to validate the manufacturing process for your dehydrated, dual layer amniotic membrane patch, TheraMend, which cannot be fully verified, to ensure that your process does not cause contamination or cross-contamination and prevents the introduction, transmission or spread of communicable disease through the use of the HCT\u002FP. Since August 2023, your firm has processed TheraMend products and distributed those products without a validated process.\n2) Failure to provide a summary of records to accompany an HCT\u002FP, that contains a listing and interpretation of the results of all communicable disease tests performed [21 CFR 1271.55(b)(2)]. Specifically, a listing and interpretation of the results of all communicable disease tests is not included on the Notification of Requirements to Maintain Traceability of Human Tissue-Based Products or Instructions for Use and Product Information forms, which are considered accompanying records as described in 21 CFR 1271.55(a).\nThe violations identified above are not intended to be an all-inclusive list of violations at your facility. It is your responsibility to ensure that your establishment complies with all applicable federal regulations. You are responsible for reviewing your firm’s operations, including firms within the same organization, as a whole to ensure that you are in compliance with the law.\nWe acknowledge receipt of your email correspondence submitted on June 30, 2025, responding to the inspectional observations. We have reviewed your response, and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response:\n• In response to Observation 1, you state that you discontinued manufacturing your Luxegen product, derived from human umbilical cord tissue, but will continue distributing Luxegen until December 1, 2025. We remain concerned about the Luxegen product that you previously distributed as well as your continued distribution of this product given its lack of approval as well as the conditions under which it was manufactured, as described in the FDA-483. We ask that you respond to this letter with your plans for addressing the Luxegen product that remains in the marketplace, within expiry, as well as confirmation that you have ceased distribution by December 1, 2025, and documentation demonstrating that you have done so.\n• In response to Observation 4a, you stated “Validation planning will being [sic] in July 2025 with all process validation activities anticipated to be completed by the end of Q2 2026.” Your response does not indicate that you will halt distribution of TheraMend products until your process has been validated. Your response also does not indicate any planned actions for the TheraMend products that have already been distributed.\nAdditionally, your response states, “Regarding product in the field, to date, we have not received any product complaints or adverse events. Similarly, the product has a straightforward manufacturing process, and an approximately 99.99% change of passing validation. It is intended as a protective covering, so we believe any product in the field is safe and of a quality manner.” This justification is insufficient. You are required to validate your process to ensure that processing prevents the introduction, transmission, or spread of communicable disease through use of the HCT\u002FP. It is your responsibility to ensure you validate all processing activities for the product(s) you are manufacturing.\n• In response to Observation 7, we acknowledge your commitment to revise procedures and retrain staff on the required summary of records as part of your CAPA #CPAR25-010. Please also ensure that a statement whether, based on the results of screening and testing, the donor has been determined to be eligible or ineligible accompanies your HCT\u002FP at all times once a donor-eligibility determination has been made in accordance with 21 CFR 1271.55(a)(2).\nYou should take prompt action to correct any violations addressed in this letter and prevent their recurrence. Failure to promptly correct any violations may result in regulatory action being initiated by FDA without further notice.\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent them, or similar violations, from occurring again. Additionally, include any documentation necessary to show that correction has been achieved. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\nYour written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\nIf you have any questions regarding this letter, please contact CBER’s Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Please be advised that only written communications are considered official.\nSincerely,\n\u002Fs\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n\n1This letter only pertains to your dehydrated, dual layer amniotic membrane patch products, TheraMend, intended to serve as a covering or barrier. Accordingly, references in this letter to HCT\u002FPs or “products” do not include products manufactured by your firm that are not regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not address those products.","Lux Therapeutics LLC dba Ponya Therapeutics LLC","lux-therapeutics-llc-dba-ponya-therapeutics-llc-720001-11252025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flux-therapeutics-llc-dba-ponya-therapeutics-llc-720001-11252025","2026-10-26T08:09:17.26833+00:00","2025-12-09","720001","Mekonnen Abebe","2026-08-19T11:24:01.502+00:00","Via UPS and EMAIL Signature Required","2025-11-25",{"id":119,"raw":120,"subject":62,"body_html":124,"body_text":125,"firm_name":126,"letter_id":127,"created_at":88,"fei_number":20,"letter_url":128,"updated_at":129,"action_type":23,"case_status":24,"posted_date":130,"marcs_cms_no":131,"product_type":50,"closeout_date":20,"issuing_office":39,"recipient_name":132,"body_fetched_at":133,"delivery_method":134,"recipient_title":20,"reference_number":135,"action_taken_date":136,"medical_device_id":20,"response_letter_date":20},621,[121,122,123,39,62,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-04T04:00:00Z\">09\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsomerset-therapeutics-private-limited-711340-09042025\">Somerset Therapeutics Private Limited \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-106\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Veerappan Subramanian\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner, Chairman, &amp; CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Somerset Therapeutics Private Limited \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>300 Franklin Square Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Somerset\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08873\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-106\u003C\u002Fp>\u003Cp>September 4, 2025\u003Cbr>\u003Cbr>Dear Mr. Subramanian:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Somerset Therapeutics Private Limited, FEI 3003821988, located at 54\u002F1 Budihal (Boodihal) Village, Nelamangala, Bengaluru, Karnataka, India, from February 10 to 21, 2025.\u003C\u002Fp>\u003Cp>This Warning Letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>The inspection also revealed that Somerset Therapeutics Private Limited failed to submit \u003Cstrong>(b)(4)\u003C\u002Fstrong> Field Alert Report (FAR) to FDA as required by section 505(k) of the FD&amp;C Act 21 U.S.C. 355(k), 21 CFR 314.81(b)(1) (NDA), \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your March 14, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to conduct adequate investigations. Investigations lacked data supporting the assigned root cause(s), were not adequately expanded to include all potentially affected drug products, or were not formally documented in your deviation system. Specifically:\u003C\u002Fp>\u003Cp>A. Your firm did not adequately investigate extensive contamination in a September 2024 media fill failure on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line. Notably, the contamination was visible to the human eye coming off the line before incubation.\u003C\u002Fp>\u003Cp>Your investigation identified the cause of the media fill failure as a breach in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank \u003Cstrong>(b)(4)\u003C\u002Fstrong> tubing and indicated that the contamination may have occurred due to operator activities.\u003C\u002Fp>\u003Cp>Your investigation also identified your ampoule filling line as having a similar equipment configuration to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line and indicated that the ampoule filling line is susceptible to the same failure mode. The investigation noted, “Over the past 2 years, no tubing damage was ever observed in the product pathway which can be readily detected in the form of leakage. Hence, a very low risk is anticipated for previously filled and completed product batches.” You did not sufficiently address the detectability of this defect or the possibility of a similar event going undetected on the ampoule filling line. You also did not adequately address contamination risks posed by vessel changeovers, nor ensure timely elimination of the use of unnecessary tubing to connect \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> vessels.\u003C\u002Fp>\u003Cp>We also note that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line was used to fill \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized drug products. Regarding the \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized drug products produced since the previous successful media fill on May 29, 2024, your investigation stated that there was “… [no] impact and no action required” and that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization cycles were “… validated using an overkill approach.” However, you failed to adequately consider the potential for high levels of contamination and the susceptibility of the isolated spore-forming organism (\u003Cem>Bacillus cereus\u003C\u002Fem>) to the sterilization process.\u003C\u002Fp>\u003Cp>B. You failed to adequately investigate out-of-specification (OOS) results for “any individual unspecified impurity” during related compound analysis of \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection validation batches and an \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution commercial batch. You identified the unspecified impurity in these drug products to be associated with an individual active pharmaceutical ingredient (API) lot used to manufacture the drug products, which exhibited a different impurity profile during the drug product shelf life when compared to exhibit batches. The investigation lacked adequate information on the root cause of the API impurity, and you did not ensure a timely response to assess the risks to other finished product batches potentially affected by the API from this supplier.\u003C\u002Fp>\u003Cp>C. You failed to review electronic data from \u003Cstrong>(b)(4)\u003C\u002Fstrong> air samplers used for environmental monitoring and ensure a timely and appropriate investigation of numerous aborted air sampler events. During the inspection, we identified at least 16 aborted air samples collected over \u003Cstrong>(b)(4)\u003C\u002Fstrong> in February 2025, within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas and corridors. The review of aborted air sampler data was limited by its unacceptable data retention capability of only 115 entries.\u003C\u002Fp>\u003Cp>Your response is inadequate. You state that the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> organisms used to validate your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization cycle is greater than the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” of the \u003Cem>B. cereus\u003C\u002Fem> organisms identified in the contaminated media. Although \u003Cem>B. cereus\u003C\u002Fem> is typically known to exhibit less \u003Cstrong>(b)(4)\u003C\u002Fstrong> than \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cem>B. cereus\u003C\u002Fem> is also known to have a relatively wide range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, with some strains exhibiting significant \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Your response did not indicate plans to evaluate the susceptibility of specific contaminating organisms found in media used to simulate drug products and drug products prior to sterilization against your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process in the future.\u003C\u002Fp>\u003Cp>You note in your response, “… \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> vessels, their tubing, the manifold, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> tubing had already been decontaminated and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> vessel (ID# PDN\u002F\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F1264) and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank (ID# PDN\u002F\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F574) which had been used to fill the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of vials had not yet been decontaminated and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” You failed to adequately maintain the equipment, thereby limiting your ability to ensure investigation and determination of the true root cause of the failure.\u003C\u002Fp>\u003Cp>Your response acknowledges a significant adverse trend of \u003Cem>B. cereus\u003C\u002Fem> contamination in your facility at the time of the media fill failure and that the route of contamination may involve employee changing rooms. Notably, you also indicate that \u003Cstrong>(b)(4)\u003C\u002Fstrong> airborne microbial monitoring is conducted in change rooms “For Information” only. Your response does not propose a systemic review and CAPA to address your environmental monitoring program.\u003C\u002Fp>\u003Cp>Your response provides an extended investigation into the impurities in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. While you collaborated with your API supplier to identify the impurities and establish new specifications, adequate CAPA activities were completed only after the inspection identified the deficiency. Your response fails to include provisions for improving ongoing lifecycle oversight of suppliers.\u003C\u002Fp>\u003Cp>We acknowledge your statement that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> air samplers are now compliant with applicable data control requirements and that you evaluated the available electronic data. However, the investigation into the aborted air samples was severely limited because of irretrievable data, resulting in an uncertain assessment of the acceptability of the environment for many marketed batches.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A further investigation into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> media fill failure that examines all potential contributing causes and includes CAPA to address them.\u003C\u002Fli>\u003Cli>An independent, comprehensive assessment of microbiological contamination risk for all distributed drug products and batches remaining within expiry that were manufactured on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and ampoule lines using \u003Cstrong>(b)(4)\u003C\u002Fstrong> tubing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> assemblies on \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks.\u003C\u002Fli>\u003Cli>Your program to assess \u003Cstrong>(b)(4)\u003C\u002Fstrong> of spore-forming microorganisms identified in product bioburden and the manufacturing environment for \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized drug products.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your personnel and environmental monitoring programs, including but not limited to a plan to fully remediate these programs. For example, describe changes to procedures, practices, and testing equipment that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging risks in your classified areas. Provide a timeline for implementation of your remediated program, including a summary of the steps you will be undertaking to ensure CAPA effectiveness.\u003C\u002Fli>\u003Cli>An evaluation of the source of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> API impurity, including CAPA that address the need to develop full impurity profiles for your supplier’s APIs.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your air samplers and how you will ensure data will be retained and reviewed. Also provide an update on your impact assessment relating to the lost data.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of electronic and paper-based documentation systems in manufacturing and laboratory operations, to identify insufficient documentation practices. Include a detailed CAPA plan to remediate data review practices and to ensure attributable, legible, complete, original, accurate, contemporaneous records.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan for computer-system security and integrity. Include a report identifying design and control vulnerabilities and the appropriate remediations for each of your laboratory and manufacturing computer systems.\u003C\u002Fli>\u003Cli>Clarify whether you will continue to use \u003Cstrong>(b)(4)\u003C\u002Fstrong> suppliers of \u003Cstrong>(b)(4)\u003C\u002Fstrong> API, and what standards will be required of these suppliers, including but not limited to, impurities.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate system for maintaining equipment used to control the aseptic conditions (21 CFR 211.42(c)(10)(vi)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On February 11, 2025, we observed that tape was being used to secure \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the interior ceiling of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line ISO 5 (Grade A) space. This tape was detached in multiple locations during the aseptic manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL (\u003Cstrong>(b)(4)\u003C\u002Fstrong> mL), batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your decision to use tape in a critical area to overcome a cleanroom deficiency raises significant concerns about your oversight of the adequacy of your facilities for aseptic processing. The detached tape may disrupt airflow within the ISO 5 space, is insanitary, cannot be cleaned, and has an adhesive side that can collect particulate contaminants. You subsequently performed airflow (smoke) studies within the ISO 5 space in an effort to assess the effect of the detached tape on airflows. You also performed surface sampling of the exposed adhesive side of the detached tape, which was intended to detect any microbiological contamination.\u003C\u002Fp>\u003Cp>Your response is inadequate. You reported that multiple personnel, working in and around the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line on February 1-2 and 6-7, 2025, did not notice any abnormalities. You therefore estimated that the tape detachment started between February 7 and 11, 2025. Your personnel reportedly did not observe detached tape while working in the area in the days preceding the FDA inspection. However, you did not conclusively show that the equipment was suitable for the aseptic manufacture of sterile drugs before FDA observed this deficiency during the inspection. Your response also did not include an investigation explaining why multiple segments of the tape became detached. You did not establish that \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL (\u003Cstrong>(b)(4)\u003C\u002Fstrong> mL), batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was the only product manufactured under these conditions. The subsequent smoke studies and use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates to perform microbiological sampling do not justify the existence of insanitary surfaces over exposed sterile drugs on an aseptic processing line.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>An amended investigation into the detached tape issue that evaluates all drug products and batches manufactured under this adverse condition, identifies the root cause(s), and includes your CAPA to address the root cause(s).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We observed multiple significant risks to product sterility during your aseptic manufacturing operations.\u003C\u002Fp>\u003Cp>\u003Cem>Interventions\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Some interventions were not adequately designed to prevent the risk of contamination. For example, operators use \u003Cstrong>(b)(4)\u003C\u002Fstrong> Restricted Access Barrier System (\u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS) \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> line to transfer materials to and from the ISO 5 area. You identify these interventions in the ISO 5 area as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” interventions, despite personnel \u003Cstrong>(b)(4)\u003C\u002Fstrong> the ISO 5 area with their hands and arms to perform various activities. Poor aseptic behaviors associated with the use of similar \u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> line were previously discussed in the October 6, 2022, regulatory meeting between your firm and FDA.\u003C\u002Fp>\u003Cp>\u003Cem>Material Transfers\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Material transfers were also deficient. For example, FDA observed that one of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> was being \u003Cstrong>(b)(4)\u003C\u002Fstrong> for extended periods of time to facilitate the transfer of sterilized stopper bags to the ISO 5 area on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line.\u003C\u002Fp>\u003Cp>\u003Cem>Airflow Studies\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Airflow studies did not allow for adequate identification and evaluation of aseptic processing hazards. For example, a video recording of the airflow study performed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> line did not include the removal of vials between the \u003Cstrong>(b)(4)\u003C\u002Fstrong> vial \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the filling machine. There was significant activity in the area where the operator was performing this manual intervention.\u003C\u002Fp>\u003Cp>Additionally, the video of an airflow study performed for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> adjustment did not allow for adequate analysis of potential hazard(s) posed by the intervention. The study did not sufficiently visualize smoke in the vicinity of the intervention.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not commit to sufficient review of aseptic processing line design, including the hazards posed by use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> (e.g., the \u003Cstrong>(b)(4)\u003C\u002Fstrong>) to perform interventions.\u003C\u002Fp>\u003Cp>Although you supplied a third-party report indicating that the videos were adequate, the report does not address the sufficiency of airflow visualization at the point of these interventions. You also state, “During \u003Cstrong>(b)(4)\u003C\u002Fstrong> intervention within the filling zone (between the sensors) in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Line, all the containers (i.e., bottles\u002Fvials) exposed from start of filling zone until stoppering zone are rejected….” However, you do not adequately address the hazard posed to empty vials on the filling line immediately adjacent to the filling zone, where airflow was interrupted during the intervention.\u003C\u002Fp>\u003Cp>We acknowledge your commitment to revise the stopper bag addition procedure to require \u003Cstrong>(b)(4)\u003C\u002Fstrong> the barrier system \u003Cstrong>(b)(4)\u003C\u002Fstrong> bag sanitizations. You further commit to modifying the \u003Cstrong>(b)(4)\u003C\u002Fstrong> design and incorporating the use of an \u003Cstrong>(b)(4)\u003C\u002Fstrong> to transfer sterilized stopper bags into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the modifications to equipment and processes are insufficient to fully address the manual hazards associated with your process design. You also do not adequately address the conditions under which, and maximum length of time, barrier system \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes but is not limited to:\u003Cbr>o All human interactions within the ISO 5 area\u003Cbr>o Equipment placement and ergonomics\u003Cbr>o Air quality in the ISO 5 area and the surrounding room\u003Cbr>o Facility layout\u003Cbr>o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003Cbr>o Maximum in-process hold times and batch processing times\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\u003Cli>Your plan to reevaluate interventions performed in airflow studies and media fills, to ensure that they appropriately reflect those taking place during commercial manufacturing operations (e.g., specific activities, duration).\u003C\u002Fli>\u003Cli>Your plan to conduct new airflow studies, by or with the assistance of one or more qualified independent third parties. Your plan should include a qualified independent third-party assessment of the airflow studies.\u003C\u002Fli>\u003Cli>Your plan to provide training for relevant personnel on the conduct and interpretation of airflow studies, to be conducted by one or more qualified third parties.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Field Alert Reporting Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The NDA\u002FANDA Field Alert reporting requirements in 21 CFR 314.81(b)(1)(ii), effective since May 23, 1985, require holders of NDAs and ANDAs to submit information concerning any bacteriological contamination, or any significant chemical, physical, or other change or deterioration in the distributed drug product, to the appropriate FDA district office within three working days of receipt by the applicant. The intent of the 21 CFR 314.81(b)(1) regulation is to establish an early warning system so that significant problems are brought to the FDA’s attention by applicant holders in order to prevent potential safety hazards from drug products already in distribution and also to prevent potential safety hazards with drug products manufactured in the future. FARs must be submitted for confirmed and unconfirmed problems meeting the definition of the regulation within three working days of becoming aware of the problem.\u003C\u002Fp>\u003Cp>From this inspection, in addition to the aforementioned CGMP violations, your firm is in violation of the Field Alert reporting requirements set forth in 21 CFR 314.81(b)(1)(ii). FARs related to a September 2024 aseptic processing simulation (media fill) failure were not provided to FDA within three working days. Specifically, you identified visually cloudy vials among the filled vials around September 30, 2024. No FAR was submitted until after the close of this inspection.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your drug products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Somerset Therapeutics Private Limited, located at Budihal (Boodihal) Village, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003821988 and ATTN: Jason Chancey and Vilmary Negrón Rodríguez.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>___________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-106\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Veerappan Subramanian\n\nRecipient Title\n\nOwner, Chairman, & CEO\n\nSomerset Therapeutics Private Limited\n\n300 Franklin Square Drive\n\nSomerset, NJ 08873\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-106\nSeptember 4, 2025\n\nDear Mr. Subramanian:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Somerset Therapeutics Private Limited, FEI 3003821988, located at 54\u002F1 Budihal (Boodihal) Village, Nelamangala, Bengaluru, Karnataka, India, from February 10 to 21, 2025.\nThis Warning Letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nThe inspection also revealed that Somerset Therapeutics Private Limited failed to submit (b)(4) Field Alert Report (FAR) to FDA as required by section 505(k) of the FD&C Act 21 U.S.C. 355(k), 21 CFR 314.81(b)(1) (NDA), (b)(4).\nWe reviewed your March 14, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYou failed to conduct adequate investigations. Investigations lacked data supporting the assigned root cause(s), were not adequately expanded to include all potentially affected drug products, or were not formally documented in your deviation system. Specifically:\nA. Your firm did not adequately investigate extensive contamination in a September 2024 media fill failure on the (b)(4) filling line. Notably, the contamination was visible to the human eye coming off the line before incubation.\nYour investigation identified the cause of the media fill failure as a breach in the (b)(4) tank (b)(4) tubing and indicated that the contamination may have occurred due to operator activities.\nYour investigation also identified your ampoule filling line as having a similar equipment configuration to the (b)(4) filling line and indicated that the ampoule filling line is susceptible to the same failure mode. The investigation noted, “Over the past 2 years, no tubing damage was ever observed in the product pathway which can be readily detected in the form of leakage. Hence, a very low risk is anticipated for previously filled and completed product batches.” You did not sufficiently address the detectability of this defect or the possibility of a similar event going undetected on the ampoule filling line. You also did not adequately address contamination risks posed by vessel changeovers, nor ensure timely elimination of the use of unnecessary tubing to connect (b)(4) to (b)(4) vessels.\nWe also note that your (b)(4) filling line was used to fill (b)(4) sterilized drug products. Regarding the (b)(4) batches of (b)(4) sterilized drug products produced since the previous successful media fill on May 29, 2024, your investigation stated that there was “… [no] impact and no action required” and that the (b)(4) sterilization cycles were “… validated using an overkill approach.” However, you failed to adequately consider the potential for high levels of contamination and the susceptibility of the isolated spore-forming organism (Bacillus cereus) to the sterilization process.\nB. You failed to adequately investigate out-of-specification (OOS) results for “any individual unspecified impurity” during related compound analysis of (b)(4) injection validation batches and an (b)(4) solution commercial batch. You identified the unspecified impurity in these drug products to be associated with an individual active pharmaceutical ingredient (API) lot used to manufacture the drug products, which exhibited a different impurity profile during the drug product shelf life when compared to exhibit batches. The investigation lacked adequate information on the root cause of the API impurity, and you did not ensure a timely response to assess the risks to other finished product batches potentially affected by the API from this supplier.\nC. You failed to review electronic data from (b)(4) air samplers used for environmental monitoring and ensure a timely and appropriate investigation of numerous aborted air sampler events. During the inspection, we identified at least 16 aborted air samples collected over (b)(4) in February 2025, within the (b)(4) areas and corridors. The review of aborted air sampler data was limited by its unacceptable data retention capability of only 115 entries.\nYour response is inadequate. You state that the “(b)(4)” of the (b)(4) organisms used to validate your (b)(4) sterilization cycle is greater than the “(b)(4)” of the B. cereus organisms identified in the contaminated media. Although B. cereus is typically known to exhibit less (b)(4) than (b)(4), B. cereus is also known to have a relatively wide range of (b)(4), with some strains exhibiting significant (b)(4).1 Your response did not indicate plans to evaluate the susceptibility of specific contaminating organisms found in media used to simulate drug products and drug products prior to sterilization against your (b)(4) sterilization process in the future.\nYou note in your response, “… (b)(4) of the (b)(4) vessels, their tubing, the manifold, and (b)(4) tubing had already been decontaminated and (b)(4). The (b)(4) vessel (ID# PDN\u002F(b)(4)\u002F1264) and the (b)(4) tank (ID# PDN\u002F(b)(4)\u002F574) which had been used to fill the (b)(4) of vials had not yet been decontaminated and (b)(4).” You failed to adequately maintain the equipment, thereby limiting your ability to ensure investigation and determination of the true root cause of the failure.\nYour response acknowledges a significant adverse trend of B. cereus contamination in your facility at the time of the media fill failure and that the route of contamination may involve employee changing rooms. Notably, you also indicate that (b)(4) airborne microbial monitoring is conducted in change rooms “For Information” only. Your response does not propose a systemic review and CAPA to address your environmental monitoring program.\nYour response provides an extended investigation into the impurities in the (b)(4) drug products. While you collaborated with your API supplier to identify the impurities and establish new specifications, adequate CAPA activities were completed only after the inspection identified the deficiency. Your response fails to include provisions for improving ongoing lifecycle oversight of suppliers.\nWe acknowledge your statement that your (b)(4) air samplers are now compliant with applicable data control requirements and that you evaluated the available electronic data. However, the investigation into the aborted air samples was severely limited because of irretrievable data, resulting in an uncertain assessment of the acceptability of the environment for many marketed batches.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA further investigation into the (b)(4) media fill failure that examines all potential contributing causes and includes CAPA to address them.\nAn independent, comprehensive assessment of microbiological contamination risk for all distributed drug products and batches remaining within expiry that were manufactured on the (b)(4) and ampoule lines using (b)(4) tubing for (b)(4) assemblies on (b)(4) tanks.\nYour program to assess (b)(4) of spore-forming microorganisms identified in product bioburden and the manufacturing environment for (b)(4) sterilized drug products.\nA comprehensive, independent review of your personnel and environmental monitoring programs, including but not limited to a plan to fully remediate these programs. For example, describe changes to procedures, practices, and testing equipment that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging risks in your classified areas. Provide a timeline for implementation of your remediated program, including a summary of the steps you will be undertaking to ensure CAPA effectiveness.\nAn evaluation of the source of the (b)(4) API impurity, including CAPA that address the need to develop full impurity profiles for your supplier’s APIs.\nA comprehensive assessment of your air samplers and how you will ensure data will be retained and reviewed. Also provide an update on your impact assessment relating to the lost data.\nA comprehensive, independent assessment of electronic and paper-based documentation systems in manufacturing and laboratory operations, to identify insufficient documentation practices. Include a detailed CAPA plan to remediate data review practices and to ensure attributable, legible, complete, original, accurate, contemporaneous records.\nA comprehensive, independent assessment and CAPA plan for computer-system security and integrity. Include a report identifying design and control vulnerabilities and the appropriate remediations for each of your laboratory and manufacturing computer systems.\nClarify whether you will continue to use (b)(4) suppliers of (b)(4) API, and what standards will be required of these suppliers, including but not limited to, impurities.\n2. Your firm failed to establish an adequate system for maintaining equipment used to control the aseptic conditions (21 CFR 211.42(c)(10)(vi)).\nOn February 11, 2025, we observed that tape was being used to secure (b)(4) to the interior ceiling of the (b)(4) filling line ISO 5 (Grade A) space. This tape was detached in multiple locations during the aseptic manufacture of (b)(4) injection, USP (b)(4) mg\u002FmL ((b)(4) mL), batch (b)(4). Your decision to use tape in a critical area to overcome a cleanroom deficiency raises significant concerns about your oversight of the adequacy of your facilities for aseptic processing. The detached tape may disrupt airflow within the ISO 5 space, is insanitary, cannot be cleaned, and has an adhesive side that can collect particulate contaminants. You subsequently performed airflow (smoke) studies within the ISO 5 space in an effort to assess the effect of the detached tape on airflows. You also performed surface sampling of the exposed adhesive side of the detached tape, which was intended to detect any microbiological contamination.\nYour response is inadequate. You reported that multiple personnel, working in and around the (b)(4) filling line on February 1-2 and 6-7, 2025, did not notice any abnormalities. You therefore estimated that the tape detachment started between February 7 and 11, 2025. Your personnel reportedly did not observe detached tape while working in the area in the days preceding the FDA inspection. However, you did not conclusively show that the equipment was suitable for the aseptic manufacture of sterile drugs before FDA observed this deficiency during the inspection. Your response also did not include an investigation explaining why multiple segments of the tape became detached. You did not establish that (b)(4) injection, USP (b)(4) mg\u002FmL ((b)(4) mL), batch (b)(4), was the only product manufactured under these conditions. The subsequent smoke studies and use of (b)(4) plates to perform microbiological sampling do not justify the existence of insanitary surfaces over exposed sterile drugs on an aseptic processing line.\nIn response to this letter, provide:\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nAn amended investigation into the detached tape issue that evaluates all drug products and batches manufactured under this adverse condition, identifies the root cause(s), and includes your CAPA to address the root cause(s).\n3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nWe observed multiple significant risks to product sterility during your aseptic manufacturing operations.\nInterventions\nSome interventions were not adequately designed to prevent the risk of contamination. For example, operators use (b)(4) Restricted Access Barrier System ((b)(4)RABS) (b)(4) on the (b)(4) line to transfer materials to and from the ISO 5 area. You identify these interventions in the ISO 5 area as “(b)(4)” interventions, despite personnel (b)(4) the ISO 5 area with their hands and arms to perform various activities. Poor aseptic behaviors associated with the use of similar (b)(4)RABS (b)(4) on the (b)(4) line were previously discussed in the October 6, 2022, regulatory meeting between your firm and FDA.\nMaterial Transfers\nMaterial transfers were also deficient. For example, FDA observed that one of the (b)(4)RABS (b)(4) was being (b)(4) for extended periods of time to facilitate the transfer of sterilized stopper bags to the ISO 5 area on the (b)(4) filling line.\nAirflow Studies\nAirflow studies did not allow for adequate identification and evaluation of aseptic processing hazards. For example, a video recording of the airflow study performed on the (b)(4) line did not include the removal of vials between the (b)(4) vial (b)(4) and the filling machine. There was significant activity in the area where the operator was performing this manual intervention.\nAdditionally, the video of an airflow study performed for the (b)(4) adjustment did not allow for adequate analysis of potential hazard(s) posed by the intervention. The study did not sufficiently visualize smoke in the vicinity of the intervention.\nYour response is inadequate. You do not commit to sufficient review of aseptic processing line design, including the hazards posed by use of the (b)(4)RABS (b)(4) (e.g., the (b)(4)) to perform interventions.\nAlthough you supplied a third-party report indicating that the videos were adequate, the report does not address the sufficiency of airflow visualization at the point of these interventions. You also state, “During (b)(4) intervention within the filling zone (between the sensors) in (b)(4) Line, all the containers (i.e., bottles\u002Fvials) exposed from start of filling zone until stoppering zone are rejected….” However, you do not adequately address the hazard posed to empty vials on the filling line immediately adjacent to the filling zone, where airflow was interrupted during the intervention.\nWe acknowledge your commitment to revise the stopper bag addition procedure to require (b)(4) the barrier system (b)(4) bag sanitizations. You further commit to modifying the (b)(4) design and incorporating the use of an (b)(4) to transfer sterilized stopper bags into the (b)(4). However, the modifications to equipment and processes are insufficient to fully address the manual hazards associated with your process design. You also do not adequately address the conditions under which, and maximum length of time, barrier system (b)(4).\nIn response to this letter, provide:\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes but is not limited to:\no All human interactions within the ISO 5 area\no Equipment placement and ergonomics\no Air quality in the ISO 5 area and the surrounding room\no Facility layout\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\no Maximum in-process hold times and batch processing times\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\nYour plan to reevaluate interventions performed in airflow studies and media fills, to ensure that they appropriately reflect those taking place during commercial manufacturing operations (e.g., specific activities, duration).\nYour plan to conduct new airflow studies, by or with the assistance of one or more qualified independent third parties. Your plan should include a qualified independent third-party assessment of the airflow studies.\nYour plan to provide training for relevant personnel on the conduct and interpretation of airflow studies, to be conducted by one or more qualified third parties.\nField Alert Reporting Violations\nThe NDA\u002FANDA Field Alert reporting requirements in 21 CFR 314.81(b)(1)(ii), effective since May 23, 1985, require holders of NDAs and ANDAs to submit information concerning any bacteriological contamination, or any significant chemical, physical, or other change or deterioration in the distributed drug product, to the appropriate FDA district office within three working days of receipt by the applicant. The intent of the 21 CFR 314.81(b)(1) regulation is to establish an early warning system so that significant problems are brought to the FDA’s attention by applicant holders in order to prevent potential safety hazards from drug products already in distribution and also to prevent potential safety hazards with drug products manufactured in the future. FARs must be submitted for confirmed and unconfirmed problems meeting the definition of the regulation within three working days of becoming aware of the problem.\nFrom this inspection, in addition to the aforementioned CGMP violations, your firm is in violation of the Field Alert reporting requirements set forth in 21 CFR 314.81(b)(1)(ii). FARs related to a September 2024 aseptic processing simulation (media fill) failure were not provided to FDA within three working days. Specifically, you identified visually cloudy vials among the filled vials around September 30, 2024. No FAR was submitted until after the close of this inspection.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your drug products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Somerset Therapeutics Private Limited, located at Budihal (Boodihal) Village, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days2. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003821988 and ATTN: Jason Chancey and Vilmary Negrón Rodríguez.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n___________________________\n1 (b)(4)\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Somerset Therapeutics Private Limited","somerset-therapeutics-private-limited-711340-09042025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsomerset-therapeutics-private-limited-711340-09042025","2026-10-26T08:10:01.429297+00:00","2025-09-16","711340","Mr. Veerappan Subramanian","2026-08-19T16:24:47.556+00:00","Via Email","320-25-106","2025-09-04",6,{"510k":139,"classification":140,"enforcement":141,"event":142,"event_backfill":143,"pma":144,"warning_letter":145},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]